Galimedix, Inc. | Finanzwire

Basculer en Français

11009	Companies
241214	Keywords
169764	Articles
129842	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 09/11/2026 at 11:35, 5 days 23 hours ago

Galimedix Therapeutics Presents Phase 2 Data at EURETINA Congress

Galimedix Therapeutics Geographic Atrophy EDREAM Study EURETINA Congress Microperimetry
PRESS RELEASE

published on 09/11/2026 at 11:30, 5 days 23 hours ago

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress on October 1-4, 2026 in Vienna, Austria

Galimedix Therapeutics Phase 2 Geographic Atrophy EDREAM Study EURETINA Congress
BRIEF

published on 03/20/2026 at 08:05, 5 months 28 days ago

Galimedix Unveils Promising Alzheimer’s Prodrug at AD/PD™ 2026

Galimedix Therapeutics Pharmacokinetic Profile Alzheimer’s Treatment Neuroprotective Therapy Oral Prodrug
PRESS RELEASE

published on 03/20/2026 at 08:00, 5 months 28 days ago

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer's candidate at AD/PD™ 2026, demonstrating improved absorption and systemic exposure for patient-friendly dosing

Alzheimer's Disease Galimedix Therapeutics Pharmacokinetic Profile Oral Alzheimer's Candidate AD/PD™ 2026
BRIEF

published on 03/12/2026 at 13:05, 6 months 4 days ago

Galimedix Therapeutics Secures Milestone Payment in Partnership with Théa

Galimedix Therapeutics Théa Open Innovation GAL-101 Trials Ophthalmology Partnership Alzheimer's Advancement
PRESS RELEASE

published on 03/12/2026 at 13:00, 6 months 4 days ago

Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation, advancing oral therapy for eye diseases and Alzheimer’s

Phase 1 Trial Alzheimer's Disease Galimedix Therapeutics Milestone Payment Ophthalmology Partnership
BRIEF

published on 03/05/2026 at 14:05, 6 months 11 days ago

Galimedix Therapeutics to Showcase New Amyloid Beta Modulator at AD/PD 2026

Neurodegenerative Disorders Galimedix Therapeutics Pharmacokinetics Amyloid Beta AD/PD 2026 Conference
PRESS RELEASE

published on 03/05/2026 at 14:00, 6 months 11 days ago

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
Galimedix Therapeutics to present pre-clinical data on new oral amyloid beta modulator at AD/PD™ 2026 Conference, discussing GAL-201 prodrugs and improved pharmacokinetics

Galimedix Therapeutics Pre-clinical Data Pharmacokinetic Profile Oral Amyloid Beta Modulator AD/PD™ 2026 Conference
BRIEF

published on 12/04/2025 at 20:20, 9 months 12 days ago

Galimedix Therapeutics Reveals Promising Phase 1 Results for GAL-101

Phase 1 Results GAL-101 Alzheimer’s Treatment Blood-brain Barrier Phase 2 Planning
PRESS RELEASE

published on 12/04/2025 at 20:15, 9 months 12 days ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Galimedix Therapeutics presents compelling Phase 1 study results at CTAD 2025, demonstrating excellent safety and pharmacokinetics of GAL-101, planning Phase 2 study in Alzheimer's disease

Alzheimer's Disease Galimedix Therapeutics GAL-101 Phase 1 Study CTAD 2025

1 2 ... 4

Accesswire

Published on 09/17/2026 at 10:00, 42 minutes ago

Eagle Plains Reports Additional Results from Drilling at the Don Lake Uranium Project, Saskatchewan
Published on 09/16/2026 at 23:45, 10 hours 57 minutes ago

Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 13 hours 12 minutes ago

Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 17 hours 47 minutes ago

CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 19 hours 42 minutes ago

2026 Canada's Top 40 Under 40(R) Honourees Announced

View all ACCESSWIRE

EQS Group

Published on 09/17/2026 at 10:05, 36 minutes ago

Geely Farizon Debuts Full-Spectrum Electric Commercial Vehicle Lineup at IAA Transportation 2026
Published on 09/17/2026 at 10:05, 36 minutes ago

Avalara Appoints Claire Goad as General Manager of E-Invoicing and Live Reporting
Published on 09/17/2026 at 09:49, 53 minutes ago

Kirchhoff analysis: Most AGM speeches in the SDAX are overly complex and lack accessibility
Published on 09/17/2026 at 09:30, 1 hour 12 minutes ago

Allane Mobility Group and DEKRA expand their network of return locations
Published on 09/17/2026 at 09:28, 1 hour 13 minutes ago

KNDS THL20 TURRETS SELECTED FOR INDIA’S NEW LIGHT COMBAT HELICOPTER PROGRAM

Les Echos

Published on 09/16/2026 at 20:46, 13 hours 56 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 16 hours 57 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 16 hours 57 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 3 hours ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 16 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE